David Berman Biography and Net Worth

Insider of Immunocore

Dr. David Berman is Head of Research and Development. Over his career, David has worked on multiple immuno-oncology (IO) programs at all stages of development, including leadership roles in developing four approved biologics. Most recently, David was Senior Vice President and Head of the AstraZeneca IO Franchise, responsible for the strategy and execution of the company’s late-stage IO program. Prior to that, he was head of the early-stage oncology program at MedImmune.

David has also held senior development roles at Bristol-Myers Squibb, including as head of the immuno-oncology exploratory development team and as Global Clinical Lead for the first approved IO checkpoint inhibitor and one of the first monoclonal antibodies approved for myeloma. Beginning in academia and throughout his industry career, David has led efforts to understand the mechanism of action of IO therapies and predict their benefit.

David received his MD and PhD from the University of Texas Southwestern Medical School. He trained in pathology at the National Cancer Institute, followed by a fellowship at The Johns Hopkins Hospital.

What is David M. Berman's net worth?: The estimated net worth of David M. Berman is at least $180.63 thousand as of February 18th, 2026. Berman owns 5,859 shares of Immunocore stock worth more than $180,633 as of April 6th. This net worth approximation does not reflect any other investments that Berman may own. Learn More about David M. Berman's net worth.
How do I contact David M. Berman?: The corporate mailing address for Berman and other Immunocore executives is 92 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0, OX14 4RY. Immunocore can also be reached via phone at 44-12-3543-8600 and via email at [email protected]. Learn More on David M. Berman's contact information.
Has David M. Berman been buying or selling shares of Immunocore?: David M. Berman has not been actively trading shares of Immunocore during the last quarter. Most recently, David M. Berman sold 5,965 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a transaction totalling $192,967.75. Following the completion of the sale, the insider now directly owns 5,859 shares of the company's stock, valued at $189,538.65. Learn More on David M. Berman's trading history.
Who are Immunocore's active insiders?: Immunocore's insider roster includes David Berman (Insider), John Goll (CAO), Bahija Jallal (CEO), and Tina St (Insider). Learn More on Immunocore's active insiders.
Are insiders buying or selling shares of Immunocore?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 41,869 shares worth more than $1,429,800.39. The most recent insider tranaction occured on February, 18th when CEO Bahija Jallal sold 11,474 shares worth more than $371,183.90. Insiders at Immunocore own 10.4% of the company. Learn More about insider trades at Immunocore.
Information on this page was last updated on 2/18/2026.

David M. Berman Insider Trading History at Immunocore

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/18/2026	Sell	5,965	$32.35	$192,967.75	5,859
9/15/2025	Sell	200	$35.01	$7,002.00
9/12/2025	Sell	22,532	$35.67	$803,716.44

David M. Berman Buying and Selling Activity at Immunocore

Immunocore Company Overview

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Today's Range

Now: $31.98

$31.17

$32.03

50 Day Range

MA: $31.91

$29.29

$35.06

2 Week Range

Now: $31.98

$23.15

$40.71

Volume

438,018 shs

Average Volume

433,167 shs

Market Capitalization

$1.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83